quinazolines has been researched along with Cancer of Prostate in 192 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.52) | 18.7374 |
| 1990's | 8 (4.17) | 18.2507 |
| 2000's | 113 (58.85) | 29.6817 |
| 2010's | 62 (32.29) | 24.3611 |
| 2020's | 8 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, P; Fan, J; Liu, C; Wang, X; Xu, C; Zhang, X; Zhao, X | 1 |
| Hasegawa, J; Hikita, T; Kugii, Y; Morioka, S; Nakanishi, H; Oneyama, C; Sakihara, T; Sasaki, J; Sasaki, T; Suzuki, A; Tokuda, E; Yamamoto, T; Yamazaki, M | 1 |
| Ahn, KS; Alharbi, SA; Blough, BE; Chinnathambi, A; Hwang, ST; Namjoshi, OA; Narula, AS; Um, JY | 1 |
| Alishahi, Z; Esmaeili, F; Ghaffari, SH; Hamzehlou, S; Karimi, B; Kashani, B; Momeny, M; Mousavi, SA; Mousavipak, SH; Nasrollahzadeh, A; Sabourinejad, Z; Sankanian, G; Shamsaiegahkani, S; Yousefi, H; Zandi, Z | 1 |
| Lin, JY; Yeh, TH | 1 |
| Chao, OS; Goodman, OB | 1 |
| Cochin, V; Godbert, Y; Gross-Goupil, M; Le Moulec, S; Ravaud, A | 1 |
| Cilia, A; Maestri, V; Minarini, A; Naldi, M; Nicolini, B; Poggesi, E; Pruccoli, L; Rosini, M; Simoni, E; Tarozzi, A | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghanizadeh-Vesali, S; Ghavamzadeh, A; Mesbahi, Y; Zekri, A | 1 |
| Abisoye-Ogunniyan, A; Davis, M; Ghebremedhin, A; Grizzle, W; Jones-Trich, J; Karanam, B; Lin, H; Salam, AB; Theodore, S; Wang, H; Yates, C | 1 |
| Hameed, I; Lin, JZ; Ren, ZY; Xu, Z; Yu, Y; Zhu, JG | 1 |
| Chu, CH; Guo, Y; Li, X; Lu, C; Luo, L; Obbad, S; Wang, KJ; Wang, Y; Yan, W; Yang, J; Zhang, R; Zhang, Y | 1 |
| Guo, Z; Huang, C; Huang, H; Jiang, L; Liao, Y; Liu, J; Liu, Y; Wang, X; Xia, X | 1 |
| Chen, YX; Dong, J; Guo, YW; Lan, WJ; Li, HJ; Ma, WZ; Shaker, S; Sun, TT; Wang, LY; Wu, DL; Yang, DP; Zhu, LP | 1 |
| Bajo, AM; Carmena, MJ; Muñoz-Moreno, L; Prieto, JC; Schally, AV | 1 |
| Adelberg, D; Chau, CH; Choyke, PL; Dahut, WL; Figg, WD; Gulley, JL; Karakunnel, JJ; Madan, RA; Mulquin, M; Parnes, HL; Spencer, SD; Steinberg, SM; Turkbey, IB; Wright, J | 1 |
| Monneret, C | 1 |
| Chen, FH; Chiang, CS; Fu, SY; Hong, JH; Wang, CC; Yang, YC | 1 |
| Bollu, LR; Gao, G; Huang, WC; Hung, MC; Ren, J; Su, F; Weihua, Z; Xu, L | 1 |
| Buchanan, G; Frydenberg, M; Furic, L; Larsson, O; Pedersen, J; Risbridger, GP; Taylor, RA; Wilkinson, SE | 1 |
| Lin, J; Pan, W; Shi, H; Wu, H; Yu, H; Zhu, J | 1 |
| Bilbro, J; Kyprianou, N; Mart, M | 1 |
| Brame, LS; Cao, A; Fang, YT; Fung, KM; Humphreys, MR; Kropp, BP; Lin, HK; Shih, PT; Wu, W; Yang, Q | 1 |
| Saya, H; Yoshida, GJ | 1 |
| Hagiyama, M; Inoue, T; Ito, A; Naito, Y; Nojima, H; Okamoto, A; Okuzaki, D; Ozaki, Y; Sakurai, MA; Sasakura, T; Tabara, H; Yabuta, N | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghanizadeh-Vesali, S; Ghavamzadeh, A; Modarressi, MH; Salmaninejad, A; Yaghmaie, M; Zekri, A | 1 |
| Bubendorf, L; Erne, P; Frachet, A; Frismantiene, A; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ; Ruiz, C; Vlajnic, T | 1 |
| Du, G; Tian, J; Wang, H; Ye, L; Yu, P; Zhang, J | 1 |
| Du, G; Tian, J; Wang, H; Ye, L; Yu, P; Zhang, J; Zuo, Y | 1 |
| Beraldi, E; Bishop, JL; Cordonnier, T; Gleave, ME; Kuruma, H; Nip, KM; Shiota, M; Takeuchi, A; Zoubeidi, A | 1 |
| Awasthi, S; Ezelle, H; Hamburger, AW; Hassel, BA | 1 |
| Bishop, KS; Denny, WA; Ferguson, LR; Lin, Z; Marlow, G; Murray, P; Sutherland, H | 1 |
| Anoopkumar-Dukie, S; Chess-Williams, R; Forbes, A; McDermott, C | 1 |
| Beckmann, L; Bender, R; Lange, S | 1 |
| Kakudo, K; Nozaki, M; Ohnishi, Y; Yasui, H | 1 |
| Benowitz, S | 1 |
| Bai, L; Chang, YM; Evans, CP; Kung, HJ; Liu, S; Yang, JC | 1 |
| Battaglia, M; Boccardo, F; Conti, G; Cruciani, G; Lapini, A; Manganelli, A; Ricci, S; Rubagotti, A | 1 |
| Beer, TM; Crawford, ED; Dakhil, SR; Drelichman, A; Goldman, B; Hussain, MH; Lara, PN; Ryan, CW; Synold, TW; Van Veldhuizen, PJ; Vasist, LS | 1 |
| Brechbiel, MW; Davis, ID; Kelly, MP; Lee, FT; Lee, ST; Scott, AM; Smyth, FE | 1 |
| Borowsky, AD; Busby, JE; Evans, CP; Kung, HJ; Ok, JH; Yang, JC | 1 |
| Corman, J; Isacson, C; Kozlowski, P; Picozzi, V; Porter, C; Vaughan, M; Vuky, J | 1 |
| Saad, F | 1 |
| JuanYin, J; Kelly, K; Koretsky, A; Munasinghe, J; Shapiro, E; Tracy, K; Zhang, L | 1 |
| Curigliano, G; de Braud, F; De Cobelli, O; Sbanotto, A; Scardino, E; Spitaleri, G | 1 |
| Chantepie, J; Fournet, G; Giliberto, JP; Goré, J; Hiltbrand, E; Mehier, H; Morel, D; Paret, MJ; Quash, G; Reichert, U; Rochedix, ME | 1 |
| Boyer, MJ; Davis, ID; Gurney, H; Kotasek, D; Pezaro, C; Rosenthal, MA; Solomon, B; Toner, GC; Underhill, C | 1 |
| Chatta, G; Evans, CP; Gandara, DR; Lara, PN; Longmate, J; Posadas, E; Quinn, DI; Stadler, W; Twardowski, P | 1 |
| Abratt, RP; Bodrogi, I; Federico, MH; Horti, J; Pover, GM; Sanders, N; Stenzl, A; Widmark, A | 1 |
| Bearss, D; Cooke, LS; Croce, KD; Mahadevan, D; Qi, W; Riley, C; Saldanha, JW; Stejskal, A | 1 |
| Batra, SK; Davis, JS; Davis, TL; Hauke, R; Lin, FF; Lin, MF; Schutte, R; Zelivianski, S; Zhang, L | 1 |
| Bromberg, ME; Colman, RW; Fusaro, M; Godoy, G; Kim, E; Liu, Y; Pixley, R | 1 |
| Biordi, L; D'Ascenzo, S; Dolo, V; Festuccia, C; Ficorella, C; Gravina, GL; Ricevuto, E; Tombolini, V | 1 |
| Bitran, JD; Galvez, A; Kelby, SK; Lestingi, TM; Nabhan, C; Newman, S; Tolzien, K; Tsarwhas, D | 1 |
| Aragon-Ching, JB; Dahut, WL | 1 |
| Collan, J; Hemminki, A; Isola, J; Joensuu, G; Joensuu, T; Kouri, M; Kupelian, PA; Nokisalmi, P; Pesonen, S; Reddy, C; Ruutu, M | 1 |
| Chin, JL; Dancey, JE; Gregg, R; Hedley, D; Hotte, SJ; Hudes, GR; Moore, MJ; Pham, NA; Sridhar, SS; Trachtenberg, J; Tran-Thanh, D; Tsao, MS; Wang, L | 1 |
| Baldi, E; Forti, G; Gelmini, S; Maggi, M; Marchiani, S; Nesi, G; Orlando, C; Paglierani, M; Tamburrino, L | 1 |
| Agus, DB; Favero, K; Hodge, A; Jain, A; Mink, S; Penuel, E; Schmidt, J; Tindell, C | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Mimeault, M | 1 |
| Arlot, Y; Depreux, P; Farce, A; Garofalo, A; Goossens, L; Lemoine, A | 1 |
| Altieri, V; De Placido, S; Di Carlo, A; Di Lorenzo, G; Ferro, M; Giordano, A; Macchia, V; Mariano, A; Mazzarella, C; Terracciano, D | 1 |
| Fozing, T; Samnick, S; Scheuer, C | 1 |
| Markaverich, BM; Rodriguez, M; Shoulars, K; Vijjeswarapu, M | 1 |
| Dondi, D; Festuccia, C; Gravina, GL; Locatelli, A; Motta, M; Piccolella, M; Tombolini, V | 1 |
| Kink, JA; Raines, RT; Rutkoski, TJ; Schilling, CI; Strong, LE | 1 |
| Kelly, K; Linnoila, RI; Munasinghe, J; Yin, JJ; Zhang, L | 1 |
| Giacalone, NJ; Kim, KW; Kopsombut, P; Lu, B; Mitchell, LR; Moretti, L; Niermann, KJ; Schleicher, SM; Sun, Y | 1 |
| Bekele, BN; Guo, CC; Marcott, V; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM; Wen, S | 1 |
| Armstrong, AJ; Crane, JM; George, DJ; Godley, PA; Grigson, G; Kim, WY; Moore, DT; Morris, K; Pruthi, RS; Rathmell, WK; Wallen, EM; Watkins, CP; Whang, YE | 1 |
| Brierley, R | 1 |
| Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
| Almendro, V; Ametller, E; Casas, I; Fernández-Nogueira, P; García-Recio, S; Gascón, P; Mayordomo, C; Pastor-Arroyo, EM; Vinyals, L | 1 |
| Chew, HK; Christensen, S; Davies, AM; Gandour-Edwards, R; Gitlitz, B; Linden, H; Mack, PC; Solis, LJ; Somlo, G; Yang, X | 1 |
| Allali-Hassani, A; Arrowsmith, CH; Barsyte-Lovejoy, D; Brown, PJ; Chen, X; Frye, SV; He, Y; Herold, JM; Huang, J; Jin, J; Liu, F; Vedadi, M; Yates, CM | 1 |
| Bubley, GJ; Carducci, M; Chen, YH; Dipaola, R; Huang, W; Kolesar, J; Liu, G; Pins, M; Stein, M; Wilding, G | 1 |
| Huang, Y; Liu, F; Liu, H; Wu, H; Zhao, L | 1 |
| Collan, J; Hemminki, A; Joensuu, G; Joensuu, T; Nupponen, N; Pesonen, S; Ruutu, M | 1 |
| Jongstra, J; Siu, A; Virtanen, C | 1 |
| Bonfil, RD; Cher, ML; Conley-LaComb, MK; Heath, E; Jung, YS; Kim, CJ; Kim, HR; Najy, AJ; Saliganan, A; Won, JJ | 1 |
| Goozner, M | 1 |
| Andreou, M; Makrigiannakis, A; Papakonstanti, EA; Stratigi, K; Tzenaki, N; Vanhaesebroeck, B; Vergetaki, A | 1 |
| Boult, JK; Elvin, P; Gilmour, LD; Halliday, J; Jacobs, V; Jamin, Y; Robinson, SP; Ryan, AJ; Walker-Samuel, S; Waterton, JC | 1 |
| Brunstein, MC; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Guérin, O; Lattanzio, L; Lo Nigro, C; Maffi, M; Merlano, M; Milano, G; Monteverde, M; Ortholan, C; Pagès, G; Sudaka, A; Tonissi, F | 1 |
| Carrión-Salip, D; De Llorens, R; Massaguer, A; Menendez, JA; Oliveras, G; Pandiella, A; Panosa, C; Puig, T | 1 |
| Caparelli, F; Hoff, PM; Sahade, M | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Aldinucci, D; Borghese, C; Cattaruzza, L; Celegato, M; Colombatti, A; De Luca, A; Mazzucato, M; Normanno, N; Pivetta, E | 1 |
| Bergeron, P; Blackwood, E; Bowman, KK; Chen, YH; Deshmukh, G; Ding, X; Epler, J; Koehler, MF; Lau, K; Lee, L; Liu, L; Ly, C; Lyssikatos, JP; Malek, S; Nonomiya, J; Oeh, J; Ortwine, DF; Pei, Z; Sampath, D; Sideris, S; Trinh, L; Truong, T; Wu, J | 1 |
| Kujala, PM; Murtola, TJ; Tammela, TL | 1 |
| Bruneteau, G; Clément, O; Cuénod, CA; Frija, G; Frouin, F; Kahn, E; Pradel, C; Siauve, N | 1 |
| Ranson, M | 1 |
| Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H | 1 |
| Chan, FL; Chang, C; Huang, J; Lee, YF; Lin, WJ; Messing, EM; Wilding, G | 1 |
| Chen, J; Lee, F; Scher, HI; She, Y; Sirotnak, FM | 1 |
| Anglin, IE; Glassman, DT; Kyprianou, N | 1 |
| Chung, T; Dent, P; Hagan, MP; Hinman, D; McKinstry, R; Yacoub, A | 1 |
| Lorusso, PM | 1 |
| Schiller, JH | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Marronaro, A; Vicentini, C | 1 |
| Anglin, IE; Kyprianou, N; Partin, JV | 1 |
| Hénichart, JP; Mimeault, M; Pommery, N | 1 |
| Blackledge, G | 1 |
| Checkley, D; Kendrew, J; Tessier, JJ; Waterton, JC; Wedge, SR | 1 |
| Kyprianou, N; Tahmatzopoulos, A | 1 |
| Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N | 1 |
| Kawashima, H; Kurisu, T; Nakatani, T; Sugimura, K; Sugita, S; Tanaka, T | 1 |
| Huang, WJ; Kan, SF; Lin, LC; Wang, PS | 1 |
| Kyprianou, N; Rowland, RG; Tahmatzopoulos, A | 1 |
| Hayter, C; Lomaga, MA | 1 |
| Baldi, E; Bonaccorsi, L; Forti, G; Marchiani, S; Muratori, M | 1 |
| Hou, SK; Liu, SJ; Wang, XF; Wang, YC; Xu, KX | 1 |
| Agrawal, S; Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Ficorella, C; Tortora, G | 1 |
| Ardito, R; Bianchino, G; Boninsegna, A; Camerini, A; Cittadini, A; Faraglia, B; Sgambato, A; Spada, D; Valentini, V | 1 |
| Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S | 1 |
| Depreux, P; Hénichart, JP; Jouy, N; Mimeault, M | 1 |
| Von Pawel, J | 1 |
| Conaway, M; Gulding, K; Nicholson, B; Theodorescu, D; Wedge, SR | 1 |
| Isoe, T; Kamishohara, M; Kubo, K; Miura, T; Nakamura, K; Shibuya, M; Taguchi, E; Takahashi, K; Yamamoto, A | 1 |
| Baldi, E; Bonaccorsi, L; Carloni, V; Forti, G; Marchiani, S; Muratori, M | 1 |
| Hansen, FD; Nexø, E; Sørensen, BS; Tørring, N; Ørntoft, TF | 1 |
| Baetz, T; Berry, S; Brundage, M; Canil, CM; Chi, KN; Douglas, L; Ernst, DS; Fisher, B; McKenna, A; Moore, MJ; Pollak, M; Seymour, L; Winquist, E | 1 |
| Vanchieri, C | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Armstrong, E; Chinnaiyan, AM; Chinnaiyan, P; Harari, PM; Huang, S; Tomlins, SA; Vallabhaneni, G; Varambally, S | 1 |
| Earp, HS; Gregory, CW; Liu, Y; Majumder, S; McCall, W; Mohler, JL; Sartor, CI; Whang, YE | 1 |
| Angelucci, A; Biordi, L; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Gérard, F; Gugenheim, J; Hannoun-Levi, JM; Mazeau, C; Milano, G | 1 |
| Halgunset, J; Larsson, E; Skogseth, H | 3 |
| Afar, DE; Agus, DB; Aronson, N; Curran, J; Galkin, A; Hunter, JB; Jain, A; Laux, I; Natale, RB; Shak, S; Tindell, CA | 1 |
| Batra, SK; Depreux, P; Hénichart, JP; Lin, MF; Mimeault, M; Moniaux, N; Moore, E | 1 |
| Chieffi, P; Cozzolino, L; De Rosa, G; Kisslinger, A; Libertini, S; Linardopoulos, S; Mansueto, G; Portella, G; Staibano, S; Tramontano, D; Villacci, A; Vitale, M | 1 |
| Angelucci, A; Biordi, L; Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Speca, S; Vicentini, C | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Melisi, D; Tortora, G; Veneziani, BM | 1 |
| Guan, JY; Hour, TC; Hsieh, MW; Huang, CY; Lin, CC; Lin, SR; Liu, GY; Pu, YS; Wang, CW | 1 |
| Brahimi, F; Jean-Claude, BJ; Merayo, N; Qiu, Q; Rachid, Z | 1 |
| Davis, DA; Hussain, M; Li, Y; Sarkar, FH; Sarkar, SH | 1 |
| Bellezza, I; Bracarda, S; Caserta, C; Minelli, A | 1 |
| Das-Gupta, A; Small, E; Soulie, P; Trump, D; Wilding, G | 1 |
| Gullick, WJ; Normanno, N | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Rucci, N; Teti, A; Vicentini, C | 1 |
| Halgunset, J; Holt, RU; Larsson, E; Skogseth, H | 1 |
| Hirata, H; Iizuka, N; Inoue, R; Matsumoto, H; Matsuyama, H; Miura, K; Naito, K; Ohmi, C; Shirai, M; Yano, S | 1 |
| Follestad, T; Halgunset, J; Larsson, E; Skogseth, H | 1 |
| Angelucci, C; Iacopino, F; Lama, G; Sica, G | 1 |
| Hoshinaga, K; Kuwahara, Y; Maruyama, T; Sakurai, T; Shiroki, R | 1 |
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
| Ciccolini, J; Ferrero, JM; Fischel, JL; Formento, P; Milano, G | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
| Bergh, A; Halin, S; Hammarsten, P; Henriksson, R; Rudolfsson, SH; Wikstöm, P | 1 |
| Briand, O; Depreux, P; Desroses, M; Farce, A; Hénichart, JP; Laconde, G; Lemoine, A; Pommery, N; Telliez, A | 1 |
| Curigliano, G; de Braud, F; De Cobelli, O; De Pas, T; Manzotti, M; Pelosi, G; Renne, G; Spitaleri, G | 1 |
| Chen, MJ; Hsu, JM; Kan, SF; Pu, HF; Wang, PS; Yu, CH | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Vankatraman, G | 1 |
| Conry, S; Hutcheon, D; Morris, C; Puchalski, T; Roth, B; Ryan, CJ; Small, EJ; Stadler, WM | 1 |
| Lupu, R; Menendez, JA | 1 |
| Borner, M; Knuth, A; Morant, R; Pedrazzini, A; Rochlitz, C; Roggero, E; Salzberg, M; Schönenberger, A; Thalmann, G | 1 |
| Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Ricevuto, E; Speca, S; Vicentini, C | 1 |
| Agus, DB; Castellanos, O; Green, E; Gross, M; Higano, C; Nguyen, K; Pantuck, A | 1 |
| Kibble, A | 1 |
| Curigliano, G; De Braud, F; De Cobelli, O; De Pas, T; Matei, V; Noberasco, C; Nolè, F; Renne, G; Rocco, B; Scardino, E; Spitaleri, G; Teresa Sandri, M; Verweij, F; Zorzino, L | 1 |
| Ceriani, I; de Eguileor, M; Del Nero, A; Magri, V; Mangiarotti, B; Marras, E; Montanari, E; Perletti, G; Trinchieri, A; Vral, A; Zirpoli, P | 1 |
| DiPaola, RS; Fontana, J; Iacona, RB; Kabbinavar, FF; Rubin, M; Small, EJ; Tannir, N; Wilding, G | 1 |
| Almaraz-Pro, C; Colás, B; Colomer, R; Cortés, MA; López-Ruiz, P; Martín-Orozco, RM; Rodríguez-Ubreva, FJ; Ropero, S | 1 |
| Barrow, D; Gee, JM; Hutcheson, IR; Jones, HE; Knowlden, JM; Nicholson, RI | 1 |
| Biordi, L; Bologna, M; Festuccia, C; Gravina, GL; Martella, O; Muzi, P; Ronchi, P; Vicentini, C | 1 |
| Bates, LF; Brackenbury, WJ; Ding, Y; Djamgoz, MB; Montano, X; Onganer, PU; Porter, LM | 1 |
| Chen, CS; Garrison, JB; Kyprianou, N; Shaw, YJ | 1 |
| Blume, JE; Miller, CC | 1 |
| Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Batra, SK; Depreux, P; Hauke, R; Henichart, JP; Lin, MF; Mehta, PP; Mimeault, M | 1 |
| Conaway, M; Gioeli, D; Theodorescu, D; Weber, MJ; Wu, Z | 1 |
| Bagattini, S; Bladou, F; Brunelle, S; Esterni, B; Gonçalves, A; Gravis, G; Marcy, M; Salem, N; Viens, P; Walz, J | 1 |
| Caine, M; Mazouz, B; Shapiro, A | 1 |
| Gautier, E; Hicks, PE; Langer, SZ; Lechaire, J; Lefèvre-Borg, F; Manoury, P; O'Connor, SE; Pierre, F; Pimoule, C; Schoemaker, H | 1 |
| Cheson, BD; Phillips, PH; Sorensen, JM | 1 |
| Barrow, D; Dutkowski, CM; Harper, ME; Jones, HE; Nicholson, RI; Wakeling, AE | 1 |
| Lavelle, F | 1 |
| Albanell, J; Baselga, J; Bos, M; Fry, DW; Kim, YM; Mendelsohn, J | 1 |
| Greenberg, NM; Kassis, J; Kim, HG; Lo, H; Moellinger, J; Wells, A | 1 |
| Guo, C; Luttrell, LM; Price, DT | 1 |
| Kris, MG; Miller, VA; Scher, HI; Sirotnak, FM; Zakowski, MF | 1 |
| Barton, J; Blackledge, G; Wakeling, A | 1 |
| Barrow, D; Dutkowski, CM; Goddard, L; Harper, ME; Jones, HE; Nicholson, RI; Smith, C | 1 |
| Benning, CM; Kyprianou, N | 1 |
| Barak, V; Eshhar, Z; Gavish, Z; Nagler, A; Pines, M; Pinthus, JH; Ramon, J | 1 |
| Assender, J; Barrow, D; Dewhurst, OL; Dutkowski, CM; Glynne-Jones, E; Goddard, L; Harper, ME; Nicholson, RI; Wakeling, AE | 1 |
| Kondo, S; Morita, T | 1 |
| Bezirdjian, L; Curley, T; Dershaw, DD; Engstrom, C; Fitzpatrick, K; Geller, N; Lin, SY; Nisselbaum, J; Scher, HI; Schwartz, M | 1 |
18 review(s) available for quinazolines and Cancer of Prostate
| Article | Year |
|---|---|
[Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].
Topics: Abatacept; Aminoglycosides; Androstenes; Androstenols; Anti-Bacterial Agents; Antineoplastic Agents; Clostridioides difficile; Clostridium Infections; Enzyme Inhibitors; Fidaxomicin; Humans; Immunoconjugates; Immunosuppressive Agents; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Thyroid Neoplasms | 2013 |
Therapeutic value of quinazoline-based compounds in prostate cancer.
Topics: Animals; Humans; Male; Prostatic Neoplasms; Quinazolines | 2013 |
Src as a therapeutic target in men with prostate cancer and bone metastases.
Topics: Antineoplastic Agents; Benzodioxoles; Bone Neoplasms; Dasatinib; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Receptors, Androgen; src-Family Kinases; Thiazoles | 2009 |
VEGF inhibitors and prostate cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Humans; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Quinazolines; Signal Transduction; Sorafenib; Thalidomide; Vascular Endothelial Growth Factors | 2009 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Sarcoma | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
ZD1839 (Iressa): for more than just non-small cell lung cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Controlled Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome | 2002 |
Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component.
Topics: Adrenergic Antagonists; Apoptosis; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Quinazolines; Receptors, Adrenergic, alpha-1; Signal Transduction; Tumor Cells, Cultured | 2002 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
New directions for ZD1839 in the treatment of solid tumors.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy.
Topics: Epidermal Growth Factor; Gefitinib; Humans; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Growth Factor | 2003 |
Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Quinazolines | 2004 |
[Anti angiogenesis].
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lung Neoplasms; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase Inhibitors; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Piperidines; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Quinazolines; Research Design; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
The role of alpha-blockers in the management of prostate cancer.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Angiogenesis Inhibitors; Anoikis; Doxazosin; Humans; Male; Prazosin; Prostatic Neoplasms; Quinazolines; Sulfonamides; Tamsulosin | 2004 |
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines | 2004 |
Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro.
Topics: Androgens; ErbB Receptors; Gefitinib; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2006 |
Growth factors and their receptors: new targets for prostate cancer therapy.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Gefitinib; Humans; Male; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Trastuzumab | 2001 |
26 trial(s) available for quinazolines and Cancer of Prostate
| Article | Year |
|---|---|
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Gefitinib; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Prednisone; Prognosis; Prostatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
Topics: Aged; Aged, 80 and over; Benzamides; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Humans; Kinesins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids | 2008 |
Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Follow-Up Studies; Gefitinib; Humans; Immunoenzyme Techniques; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms; Quinazolines; Risk Factors; Taxoids; Treatment Outcome | 2009 |
Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.
Topics: Activities of Daily Living; Adenocarcinoma; Administration, Oral; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Pain; Pain Measurement; Prostatic Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Time Factors; Treatment Failure | 2009 |
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Risk Assessment; Single-Blind Method; Survival Analysis; Testosterone; Treatment Outcome | 2009 |
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzodioxoles; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Gastrointestinal Diseases; Humans; Lymphopenia; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2009 |
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Piperidines; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2009 |
Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Prostatic Neoplasms; Quinazolines | 2009 |
A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Interleukin-1alpha; Interleukin-6; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Radiotherapy Dosage; Tumor Necrosis Factor-alpha | 2010 |
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Risk Assessment; Single-Blind Method; Survival Rate; Treatment Outcome | 2010 |
Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Male; Middle Aged; Piperazines; Prostatic Neoplasms; Quinazolines; Receptors, Platelet-Derived Growth Factor; Survival Rate | 2011 |
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Castration; ErbB Receptors; Follow-Up Studies; Humans; Lapatinib; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate | 2013 |
Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Single Nucleotide; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2013 |
A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy.
Topics: Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Gefitinib; Humans; Male; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Skin; Treatment Outcome | 2002 |
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines | 2005 |
Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Estramustine; Gefitinib; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids | 2006 |
Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Male; Mutation; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines | 2007 |
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Gefitinib; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Erlotinib Hydrochloride; Humans; Male; Prostatic Neoplasms; Quality of Life; Quinazolines; Survival Rate; Taxoids | 2007 |
Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progression; Drug Resistance, Neoplasm; Endpoint Determination; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Immunohistochemistry; Male; Middle Aged; Pain Measurement; Prostatic Neoplasms; Quality of Life; Quinazolines; Surveys and Questionnaires | 2007 |
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Probability; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
148 other study(ies) available for quinazolines and Cancer of Prostate
| Article | Year |
|---|---|
Identification of evodiamine as a suppressor of prostate cancer progression by reducing AR transcriptional activity via targeting Src.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Prostate; Prostatic Neoplasms; Quinazolines; Receptors, Androgen | 2022 |
A mass spectrometric method for in-depth profiling of phosphoinositide regioisomers and their disease-associated regulation.
Topics: Animals; Chromatography, Affinity; Class I Phosphatidylinositol 3-Kinases; Epidermal Growth Factor; Exosomes; Gene Expression; HEK293 Cells; HeLa Cells; Humans; Male; Mass Spectrometry; Metabolome; Mice; PC-3 Cells; Phosphatidylinositols; Prostate; Prostatic Neoplasms; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Stereoisomerism | 2022 |
Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA Damage; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Silencing; Hepatocyte Growth Factor; Humans; Male; Models, Biological; Neoplasm Proteins; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor | 2020 |
Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Docetaxel; Gamma Rays; Gene Expression Regulation; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Receptors, Vascular Endothelial Growth Factor | 2020 |
Rutaecarpine administration inhibits cancer cell growth in allogenic TRAMP-C1 prostate cancer mice correlating with immune balance in vivo.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; Body Weight; Cachexia; Cell Line, Tumor; Cell Transformation, Neoplastic; Cytokines; Dose-Response Relationship, Drug; Indole Alkaloids; Lymphocyte Count; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Organ Size; Prostatic Neoplasms; Quinazolines; Spleen; Th1-Th2 Balance; Tumor Necrosis Factor-alpha | 2021 |
DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chromones; DNA Damage; DNA-Activated Protein Kinase; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Morpholines; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Taxoids | 2021 |
[Cabozantinib: Mechanism of action, efficacy and indications].
Topics: Anilides; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Quinazoline based α
Topics: Adrenergic alpha-1 Receptor Antagonists; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Male; Molecular Structure; Prostatic Neoplasms; Quinazolines; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA.
Topics: Aurora Kinase B; Cell Line, Tumor; Cell Survival; Humans; Male; Mitochondria; Neoplastic Stem Cells; Organophosphates; Polyploidy; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species | 2017 |
Transcriptional repressor Kaiso promotes epithelial to mesenchymal transition and metastasis in prostate cancer through direct regulation of miR-200c.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; ErbB Receptors; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Metastasis; Neoplasm Transplantation; Prostatic Neoplasms; Quinazolines; Transcription Factors | 2018 |
Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Prostatic Neoplasms; Quinazolines; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Inhibition of Karyopherin beta 1 suppresses prostate cancer growth.
Topics: Animals; beta Karyopherins; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; PC-3 Cells; Prostatic Neoplasms; Quinazolines; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2019 |
Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.
Topics: Animals; Apoptosis; Autophagy; Benzamides; Benzylamines; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Disease Models, Animal; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Glucose; Glucose Transporter Type 1; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Models, Biological; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Reactive oxygen species altering the metabolite profile of the marine-derived fungus
Topics: Animals; Antineoplastic Agents; Aspergillus; Culture Media; Diketopiperazines; Drug Screening Assays, Antitumor; Ergosterol; Humans; Hydrogen Peroxide; Indoles; Male; Melanoma; Mice; Molecular Structure; Prostatic Neoplasms; Quinazolines; Reactive Oxygen Species; Secondary Metabolism | 2021 |
Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists.
Topics: Androgens; Cell Adhesion; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Growth Hormone-Releasing Hormone; Humans; Male; Neuroendocrine Cells; PC-3 Cells; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Tyrphostins | 2020 |
Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzimidazoles; Benzylamines; Bone Marrow Cells; Chemokine CXCL12; Combined Modality Therapy; Cyclams; Dose Fractionation, Radiation; ErbB Receptors; Gefitinib; Green Fluorescent Proteins; Heterocyclic Compounds; Luminescent Agents; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pericytes; Prostatic Neoplasms; Quinazolines; Receptors, CXCR4; Tumor Microenvironment | 2013 |
EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Male; Phosphorylation; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Sodium-Glucose Transporter 1 | 2013 |
Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium.
Topics: Animals; Benzamides; Cell Communication; Cell Differentiation; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Epithelium; Fibroblasts; Hedgehog Proteins; Heterografts; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Morpholines; Prostatic Neoplasms; Purines; Quinazolines; Signal Transduction; Stromal Cells | 2013 |
Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Proliferation; Cyclooxygenase 2; Docetaxel; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Nitrobenzenes; Prostatic Neoplasms; Quinazolines; Sulfonamides; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
Topics: Autocrine Communication; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; GABA Agonists; GABA Antagonists; gamma-Aminobutyric Acid; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Isonicotinic Acids; Male; Paracrine Communication; Phosphorylation; Picrotoxin; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, GABA-A; Signal Transduction; src-Family Kinases | 2014 |
EpCAM expression in the prostate cancer makes the difference in the response to growth factors.
Topics: AMP-Activated Protein Kinases; Antigens, Neoplasm; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Line, Tumor; Epidermal Growth Factor; Epithelial Cell Adhesion Molecule; ErbB Receptors; Gefitinib; Humans; Large Neutral Amino Acid-Transporter 1; Male; Neoplastic Stem Cells; Prostatic Neoplasms; Quinazolines; Signal Transduction; Tumor Microenvironment | 2014 |
Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Luteolin; Male; MicroRNAs; Models, Biological; Neoplasm Grading; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Quinazolines; Signal Transduction | 2014 |
AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy.
Topics: Aneugens; Animals; Apoptosis; Aurora Kinase B; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Male; Mice; Micronuclei, Chromosome-Defective; Organophosphates; Prostatic Neoplasms; Quinazolines; Receptors, Androgen; Xenograft Model Antitumor Assays | 2015 |
EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by T-cadherin.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Survival; Collagen; Drug Combinations; ErbB Receptors; Gefitinib; Gene Silencing; Golgi Apparatus; Humans; Laminin; Male; Neoplasm Invasiveness; Phenotype; Phosphorylation; Prostate; Prostatic Neoplasms; Proteoglycans; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1 | 2015 |
NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; HCT116 Cells; Hep G2 Cells; HT29 Cells; Humans; Male; MAP Kinase Kinase Kinases; MCF-7 Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Quinazolines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2015 |
NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Discovery; Enzyme Activation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Quinazolines; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2014 |
Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Topics: Adenocarcinoma; Androgen Receptor Antagonists; Animals; Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lapatinib; Male; Mice; Mice, Nude; Neoplasm Proteins; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Signal Transduction; Y-Box-Binding Protein 1 | 2015 |
The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Androgens; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Androgen; RNA-Binding Proteins; Signal Transduction | 2015 |
A quinazoline-based HDAC inhibitor affects gene expression pathways involved in cholesterol biosynthesis and mevalonate in prostate cancer cells.
Topics: Cell Line, Tumor; Cholesterol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Male; Mevalonic Acid; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Quinazolines; Reproducibility of Results; Signal Transduction | 2016 |
Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Cell Survival; Doxazosin; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Male; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prazosin; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides; Tamsulosin | 2016 |
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.
Topics: Adverse Drug Reaction Reporting Systems; Androstenes; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Humans; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Survival Rate; Thyroid Neoplasms | 2016 |
Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Cyclin D2; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Mouth Neoplasms; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2016 |
As metastasis yields its biological secrets, researchers hope to apply findings.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Denosumab; Drug Design; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Quinazolines; RANK Ligand; Receptor, ErbB-2; Trastuzumab | 2008 |
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Topics: Antineoplastic Agents; Benzodioxoles; beta Catenin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crk-Associated Substrate Protein; Cyclin D; Cyclins; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Molecular Structure; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Quinazolines; Repressor Proteins; src-Family Kinases; Time Factors | 2008 |
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Humans; Isothiocyanates; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Phosphorylation; Prostatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radioimmunotherapy; Radioisotopes; Taxoids; Tyrphostins; Xenograft Model Antitumor Assays | 2009 |
Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.
Topics: Androgen Receptor Antagonists; Animals; Benzodioxoles; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Enzyme Activation; Focal Adhesion Kinase 1; Gastrin-Releasing Peptide; Genetic Vectors; Humans; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Androgen; src-Family Kinases; Transfection; Xenograft Model Antitumor Assays | 2009 |
Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model.
Topics: Animals; Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Disease Models, Animal; Ferric Compounds; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Prostatic Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Synergetic bitherapy in mice with xenografts of human prostate cancer using a methional mimic (METLICO) and an aldehyde dehydrogenase 3 inhibitor (MATE): systemic intraperitoneal (IP) and targeted intra-tumoral (IT) administration.
Topics: Aldehyde Dehydrogenase; Aldehydes; Animals; Biomimetics; Combined Modality Therapy; Drug Delivery Systems; Enzyme Inhibitors; Female; Humans; Injections, Intralesional; Injections, Intraperitoneal; Male; Mice; Mice, Nude; Molecular Structure; Morpholines; Prostatic Neoplasms; Quinazolines; Tumor Burden | 2009 |
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Mice, SCID; Multigene Family; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thiourea | 2009 |
Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.
Topics: Androgens; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gemcitabine; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Time Factors; Tyrphostins | 2009 |
Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway.
Topics: Cell Line, Tumor; Cell Movement; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Kininogen, High-Molecular-Weight; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Protein Structure, Tertiary; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Tyrphostins | 2009 |
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.
Topics: Apoptosis; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Receptors, Androgen; RNA, Small Interfering; Signal Transduction | 2009 |
Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.
Topics: Androgens; Cell Differentiation; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Neuroendocrine Cells; Phosphopyruvate Hydratase; Prostatic Neoplasms; Quinazolines; Receptors, Androgen | 2010 |
HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation.
Topics: Animals; Cell Growth Processes; Cell Line, Tumor; Dimerization; Down-Regulation; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Up-Regulation | 2010 |
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
Topics: Adenocarcinoma; Apoptosis; Cell Fractionation; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Humans; Male; Neoplasm Invasiveness; Phosphorylation; Prostate; Prostatic Neoplasms; Quinazolines; Taxoids; Transcription Factors; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2010 |
Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Topics: Amides; Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Urea; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content.
Topics: Androgens; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoma; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Chromogranin A; Cytosol; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Male; Osteopontin; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2 | 2010 |
Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer.
Topics: Animals; Antibodies, Monoclonal; Biological Transport; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hormones; Humans; Iodine Radioisotopes; Male; Mice; Molecular Imaging; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Rats; Tomography; Xenograft Model Antitumor Assays | 2010 |
Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Luteolin; Male; Prostatic Neoplasms; Quinazolines; Signal Transduction | 2010 |
Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Division; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gonadotropin-Releasing Hormone; Humans; Male; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Quinazolines; Tumor Cells, Cultured | 2010 |
Antitumor activity of ribonuclease multimers created by site-specific covalent tethering.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Proliferation; Enzyme Inhibitors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Prostatic Neoplasms; Protein Binding; Quinazolines; Ribonuclease, Pancreatic; Sulfhydryl Compounds; Tumor Cells, Cultured | 2010 |
Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer.
Topics: Animals; Blotting, Western; Bone Neoplasms; Brain Neoplasms; Humans; Immunoenzyme Techniques; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Quinazolines; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition.
Topics: Androgens; Aurora Kinase B; Aurora Kinases; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Male; Organophosphates; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Quinazolines; Radiation Tolerance; Treatment Failure; Treatment Outcome | 2011 |
2011 ASCO Genitourinary Cancers Symposium.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Humans; Kidney Neoplasms; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2011 |
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Male; Neoplasms; Neurokinin-1 Receptor Antagonists; Piperidines; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Neurokinin-1; Signal Transduction; Substance P; Trastuzumab | 2012 |
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
Topics: Blotting, Western; Breast Neoplasms; Cell Proliferation; Colonic Neoplasms; Enzyme Inhibitors; Female; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Male; Models, Molecular; Prostatic Neoplasms; Protein Binding; Protein Conformation; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
Anti-tumour activity of 4-(4-fluorophenyl)amino-5,6,7-trimethoxyquinazoline against tumour cells in vitro.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prostatic Neoplasms; Quinazolines; Signal Transduction | 2012 |
PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; MAP Kinase Signaling System; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-pim-1; Pyridazines; Quinazolines; RNA Interference; RNA, Small Interfering; Tumor Suppressor Proteins | 2011 |
Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Growth Inhibitors; Humans; Lymphokines; Male; Mice; Mice, SCID; Platelet-Derived Growth Factor; Prostatic Neoplasms; Quinazolines; Random Allocation; Xenograft Model Antitumor Assays | 2012 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation.
Topics: Adenine; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class Ia Phosphatidylinositol 3-Kinase; Female; Male; Mice; NIH 3T3 Cells; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Isoforms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2012 |
False-negative MRI biomarkers of tumour response to targeted cancer therapeutics.
Topics: Animals; Benzodioxoles; Biomarkers, Tumor; Blood Vessels; Cell Hypoxia; Cell Line, Tumor; False Negative Reactions; Female; Humans; Magnetic Resonance Imaging; Male; Mammary Neoplasms, Experimental; Mice; Molecular Targeted Therapy; Neoplasm Transplantation; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Rats; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred Strains; Piperidines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2013 |
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Topics: Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Betacellulin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Male; Neuregulin-1; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger | 2012 |
Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.
Topics: Cell Communication; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Chemokine CCL5; Chemotaxis; Culture Media, Conditioned; Docetaxel; ErbB Receptors; Gefitinib; Humans; Male; Mesenchymal Stem Cells; Osteoblasts; Osteoclasts; Osteogenesis; Phosphorylation; Prostatic Neoplasms; Quinazolines; Subcellular Fractions; Taxoids | 2013 |
Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Nude; Molecular Docking Simulation; Multiprotein Complexes; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Prostatic Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2012 |
High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Cohort Studies; Disease-Free Survival; Dutasteride; Finasteride; Finland; Humans; Kallikreins; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quinazolines; Sulfonamides; Survival Rate; Tamsulosin | 2013 |
Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media.
Topics: Animals; Capillary Permeability; Contrast Media; Endothelial Growth Factors; Gadolinium; Heterocyclic Compounds; Intercellular Signaling Peptides and Proteins; Lymphokines; Macromolecular Substances; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; Organometallic Compounds; Perfusion; Prostatic Neoplasms; Quinazolines; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Topics: Androgen Antagonists; Cell Division; Cyclin D1; Enzyme Activation; ErbB Receptors; Flutamide; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-raf; Quinazolines; ras Proteins; Receptors, Androgen; Substance Withdrawal Syndrome; Tyrphostins | 2002 |
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carboplatin; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Androgen; Testosterone; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling.
Topics: Adenocarcinoma; Autocrine Communication; Cobalt Radioisotopes; DNA Damage; DNA Repair; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Flavonoids; Gamma Rays; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Prostatic Neoplasms; Protein Biosynthesis; Proteins; Quinazolines; Tumor Cells, Cultured; Tyrphostins; X-ray Repair Cross Complementing Protein 1 | 2003 |
Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; In Vitro Techniques; Male; Phosphorylation; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured; Tyrosine | 2003 |
Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction.
Topics: Adrenergic alpha-Antagonists; AMP-Activated Protein Kinase Kinases; Apoptosis; Caspase 3; Caspases; Doxazosin; Gene Expression Regulation, Neoplastic; Humans; Male; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Quinazolines; Receptors, Adrenergic, alpha-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transforming Growth Factor beta | 2003 |
Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Cell Division; Cell Separation; Ceramides; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Humans; Male; Membrane Potentials; Mitochondria; Necrosis; Prostatic Neoplasms; Protease Inhibitors; Quinazolines; Tumor Cells, Cultured | 2003 |
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.
Topics: Adenocarcinoma; Animals; Capillary Permeability; Contrast Media; Dose-Response Relationship, Drug; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasms, Experimental; Piperidines; Prostatic Neoplasms; Quinazolines; Reproducibility of Results; Signal Transduction; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2003 |
Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor.
Topics: Androgens; Enzyme Inhibitors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ligands; Luciferases; Male; Mitogen-Activated Protein Kinases; Phosphorylation; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Trans-Activators; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 2004 |
Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspases; CDC2 Protein Kinase; Cell Cycle; Cell Division; Cell Line, Tumor; Coloring Agents; Dose-Response Relationship, Drug; Flow Cytometry; G2 Phase; Histones; Humans; In Situ Nick-End Labeling; L-Lactate Dehydrogenase; Male; Mitosis; Models, Chemical; Plant Extracts; Ploidies; Prostatic Neoplasms; Quinazolines; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
Priapism as a possible acute side effect of radical radiotherapy for prostate cancer.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Priapism; Prostate; Prostatic Neoplasms; Quinazolines; Radiotherapy; Radiotherapy Dosage | 2004 |
Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.
Topics: Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunoprecipitation; In Situ Nick-End Labeling; Male; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
[The growth inhibition effect of alpha-adrenoceptor antagonists on androgen- independent prostate cancer cell line].
Topics: Adrenergic alpha-Antagonists; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Male; Phenoxybenzamine; Prazosin; Prostatic Neoplasms; Quinazolines | 2004 |
Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Nuclear Proteins; Oligonucleotides, Antisense; Phosphorylation; Prostatic Neoplasms; Protein Biosynthesis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Quinazolines; Time Factors; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
Topics: Androgen Antagonists; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; ErbB Receptors; Flutamide; Gefitinib; Humans; Male; Prostatic Neoplasms; Quinazolines; Tumor Suppressor Proteins | 2004 |
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Division; Cell Line, Tumor; Ceramides; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Male; Mitochondria; Nitric Oxide Donors; Nitroprusside; Prostatic Neoplasms; Quinazolines; Reactive Oxygen Species | 2005 |
Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
Topics: Androgens; Angiogenesis Inhibitors; Animals; Castration; Cell Division; Combined Modality Therapy; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Orchiectomy; Piperidines; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2004 |
KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth.
Topics: Angiogenesis Inhibitors; Animals; Cell Proliferation; Colonic Neoplasms; Endothelial Cells; Enzyme Activation; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Phosphorylation; Prostatic Neoplasms; Quinazolines; Rats; Rats, Nude; Transplantation, Heterologous; Tyrosine; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Signaling mechanisms that mediate invasion in prostate cancer cells.
Topics: Androgens; Cell Line, Tumor; Cell Proliferation; Collagen; Drug Combinations; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Laminin; Male; Neoplasm Invasiveness; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Proteoglycans; Quinazolines; Receptors, Androgen; Signal Transduction; Transfection; Tyrosine | 2004 |
Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition.
Topics: Amphiregulin; Androgens; Animals; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Gefitinib; Gene Expression; Glycoproteins; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Orchiectomy; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2005 |
Scientists hopeful as they uncover molecular clues to prostate cancer.
Topics: Androgen Receptor Antagonists; Androgens; Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; Phosphoric Monoester Hydrolases; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; PTEN Phosphohydrolase; Quinazolines; Receptors, Androgen; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Up-Regulation | 2005 |
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dihydrotestosterone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Tosyl Compounds; Transplantation, Heterologous | 2005 |
Top 10 health stories of 2004.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antidepressive Agents; Antineoplastic Agents; Biomedical Research; Cholesterol, LDL; Cloning, Organism; Coronary Disease; Delivery of Health Care; Dementia; Gefitinib; Humans; Influenza Vaccines; Insurance, Health; Lactones; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Registries; Sulfones; Walking | 2004 |
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Quinazolines; Rad51 Recombinase; Radiation-Sensitizing Agents; Signal Transduction; Xenograft Model Antitumor Assays | 2005 |
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Topics: Acetylation; Androgen Receptor Antagonists; Androgens; Cell Line, Tumor; Chromatin; Chromatin Immunoprecipitation; Dihydrotestosterone; ErbB Receptors; Gefitinib; Histones; Humans; Immunoglobulin Fragments; Lapatinib; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Response Elements; Transcription, Genetic | 2005 |
Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Topics: Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Chemotaxis; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Laminin; Male; MAP Kinase Signaling System; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Diacylglycerol-Lyase; Phosphoinositide Phospholipase C; Phosphoric Monoester Hydrolases; Phosphorylation; Prostatic Neoplasms; Proteoglycans; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Proteins; Urokinase-Type Plasminogen Activator | 2005 |
Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Quinazolines; Trastuzumab; Xenograft Model Antitumor Assays | 2005 |
Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Genistein; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured; Tyrphostins; Urokinase-Type Plasminogen Activator | 2005 |
Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Models, Animal; Mutation; Neoplasm Proteins; Prostatic Neoplasms; Quinazolines; Receptors, Cell Surface; Xenograft Model Antitumor Assays | 2005 |
Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Proliferation; DNA Damage; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Male; Prostatic Neoplasms; Quinazolines; Signal Transduction; Trans-Activators; Tumor Cells, Cultured; Veratrum Alkaloids | 2006 |
Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation.
Topics: Aurora Kinase B; Aurora Kinases; Blotting, Western; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Flow Cytometry; Histones; Humans; Immunohistochemistry; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2006 |
Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; ErbB Receptors; G1 Phase; Gefitinib; Humans; Male; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2005 |
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proteins; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays; Zoledronic Acid | 2005 |
Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.
Topics: Adenocarcinoma; Androgens; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Male; Paclitaxel; Prostatic Neoplasms; Quinazolines | 2006 |
The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo.
Topics: Acetylation; Animals; Cell Proliferation; Chromatography, High Pressure Liquid; Chromatography, Liquid; ErbB Receptors; Humans; Male; Mass Spectrometry; Mice; Prostatic Neoplasms; Quinazolines; Triazenes; Tumor Cells, Cultured | 2006 |
Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line.
Topics: Antimitotic Agents; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA; DNA Primers; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Genistein; Histones; Humans; Isoflavones; Kinesins; Male; Models, Statistical; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Spindle Apparatus; Tetrazolium Salts; Thiazoles | 2006 |
The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.
Topics: Basement Membrane; Biological Assay; Carcinoma; Cell Movement; Collagen; Drug Combinations; Genistein; Humans; Laminin; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Plasminogen; Plasminogen Activators; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteoglycans; Quinazolines; Tyrphostins | 2006 |
Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?
Topics: Antineoplastic Agents; Bone Neoplasms; ErbB Receptors; Gefitinib; Humans; Male; Prostatic Neoplasms; Quinazolines; Signal Transduction | 2006 |
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; ErbB Receptors; Gefitinib; Humans; Immunoprecipitation; Incidence; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Prostatic Neoplasms; Quinazolines; Signal Transduction; Stromal Cells; Xenograft Model Antitumor Assays | 2006 |
Tyrosine kinase inhibitors alter adhesivity of prostatic cancer cells to extracellular matrix components.
Topics: Cell Adhesion; Cell Line, Tumor; Cell Survival; Extracellular Matrix; Genistein; Humans; Integrins; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tyrphostins | 2006 |
Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.
Topics: Androgens; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression; Humans; Male; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines | 2006 |
Urokinase plasminogen activator receptor (uPAR) expression is reduced by tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Cell Line, Tumor; Gene Expression; Genistein; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; RNA, Messenger; Tyrphostins | 2006 |
Transcription levels of invasion-related genes in prostate cancer cells are modified by inhibitors of tyrosine kinase.
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genistein; Humans; Male; Metalloproteases; Prostatic Neoplasms; Protein Array Analysis; Protein-Tyrosine Kinases; Quinazolines; RNA, Messenger; Transcription, Genetic; Tyrphostins; Urokinase-Type Plasminogen Activator | 2006 |
Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Humans; Leuprolide; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasms, Hormone-Dependent; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Tyrphostins | 2006 |
[Effectiveness of taxanes-based chemotherapy against hormone-refractory prostate carcinoma].
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Gefitinib; Humans; Male; Mice; Middle Aged; Prognosis; Prostatic Neoplasms; Quality of Life; Quinazolines; Taxoids | 2006 |
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |
Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Size; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Floxuridine; Humans; Male; Prostatic Neoplasms; Quinazolines; Taxoids; Thymidine Phosphorylase; Thymidylate Synthase | 2006 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma; Castration; Combined Modality Therapy; Dose-Response Relationship, Drug; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2006 |
Derivatives of Iressa, a specific epidermal growth factor receptor inhibitor, are powerful apoptosis inducers in PC3 prostatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3.
Topics: Androgens; Apoptosis; Carcinoma; Caspase 3; Caspase 8; Caspase 9; CDC2 Protein Kinase; Cell Division; Cell Line, Tumor; Culture Media; Cyclin B; Cyclin B1; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; G2 Phase; Humans; L-Lactate Dehydrogenase; Male; Plant Extracts; Prostatic Neoplasms; Purines; Quinazolines; Roscovitine | 2007 |
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cytochromes c; Docetaxel; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Immunohistochemistry; Male; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quinazolines; Signal Transduction; Taxoids; Tumor Cells, Cultured; Veratrum Alkaloids | 2007 |
Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Prostatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2007 |
Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gefitinib; Humans; Male; Nerve Growth Factor; Phosphorylation; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, Nerve Growth Factor; Receptor, trkA; Receptor, trkB; Signal Transduction; Time Factors | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Algorithms; Androgen Antagonists; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Biomarkers, Tumor; Biopsy; Ciprofloxacin; Drug Therapy, Combination; Humans; Male; Middle Aged; Plant Extracts; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatitis; Quinazolines; Retrospective Studies; Serenoa | 2007 |
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Topics: Adenocarcinoma; Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Differentiation; Cell Line, Tumor; Culture Media, Serum-Free; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunoprecipitation; Insulin Receptor Substrate Proteins; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Cross-Talk; Receptors, Somatomedin; Signal Transduction | 2008 |
Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.
Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Tosyl Compounds | 2007 |
Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer cells partially via voltage-gated Na+ channel activity.
Topics: Animals; Cell Movement; Epidermal Growth Factor; Ion Channel Gating; Male; Prostatic Neoplasms; Quinazolines; Rats; Sodium Channels; Tetrodotoxin; Tyrphostins; Up-Regulation | 2008 |
Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity.
Topics: Adrenergic alpha-Antagonists; Animals; Apoptosis; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Chickens; Chorioallantoic Membrane; Doxazosin; Endothelium, Vascular; Humans; Integrin beta1; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Quinazolines; Umbilical Veins | 2007 |
Livedo reticularis with retiform purpura associated with gefitinib (Iressa).
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Livedo Reticularis; Male; Prostatic Neoplasms; Purpura; Quinazolines; Skin | 2007 |
Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
Topics: Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Enzyme Activation; Epidermal Growth Factor; Erlotinib Hydrochloride; Flow Cytometry; Humans; Male; Morpholines; Neoplasms, Hormone-Dependent; Phosphorylcholine; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2008 |
Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Hydrogen Peroxide; Male; Membrane Potential, Mitochondrial; Mitoxantrone; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quinazolines; Signal Transduction; Veratrum Alkaloids | 2007 |
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; ErbB Receptors; Gefitinib; Humans; Lapatinib; Male; Mitogen-Activated Protein Kinases; Morpholines; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines | 2008 |
The alpha-adrenergic blocking effect of prazosin on the human prostate.
Topics: Adenoma; Adrenergic alpha-Antagonists; Humans; Male; Muscle Contraction; Prazosin; Prostate; Prostatic Neoplasms; Quinazolines; Receptors, Adrenergic; Receptors, Adrenergic, alpha | 1981 |
Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract.
Topics: Adenofibroma; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Cats; Decerebrate State; Electric Stimulation; Female; Heart; Humans; In Vitro Techniques; Male; Phenylephrine; Prazosin; Prostatic Neoplasms; Quinazolines; Rabbits; Rats; Sympathetic Nervous System; Tumor Cells, Cultured; Urethra; Urinary Tract; Vasoconstriction | 1993 |
Clinical trials referral resource. Clinical trials with tomudex.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Folic Acid Antagonists; Head and Neck Neoplasms; Humans; Leukemia; Male; Prostatic Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase | 1996 |
New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145.
Topics: Cell Division; Enzyme Inhibitors; ErbB Receptors; Humans; Immunohistochemistry; Male; Phosphorylation; Prostatic Neoplasms; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 1997 |
[Tyrosine protein kinase inhibitors in cancerology: the end of the beginning?].
Topics: Animals; ErbB Receptors; Humans; In Vitro Techniques; Male; Mice; Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Rats; Staurosporine; Structure-Activity Relationship | 1997 |
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Enzyme Inhibitors; ErbB Receptors; Female; Genes, erbB-2; Humans; Male; Phosphorylation; Prostatic Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Recombinant Proteins; Transfection; Uterine Cervical Neoplasms; Vulvar Neoplasms | 1997 |
A role for phospholipase C-gamma-mediated signaling in tumor cell invasion.
Topics: Adenocarcinoma; Animals; Autocrine Communication; Breast Neoplasms; Cell Line; Diffusion Chambers, Culture; Epidermal Growth Factor; ErbB Receptors; Estrenes; Female; Humans; Immunoblotting; Isoenzymes; Male; Mice; Neoplasm Invasiveness; Phosphodiesterase Inhibitors; Phospholipase C gamma; Phosphorylation; Prostatic Neoplasms; Pyrrolidinones; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Type C Phospholipases | 1999 |
Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines.
Topics: Cell Division; Dihydrotestosterone; Enzyme Inhibitors; Epidermal Growth Factor; Flavonoids; Humans; Male; Mitogen-Activated Protein Kinases; Phosphorylation; Prostatic Neoplasms; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 2000 |
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Topics: Aminopterin; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Vulvar Neoplasms | 2000 |
Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways.
Topics: Androgen Antagonists; Anilides; Blotting, Western; Cell Division; Drug Interactions; Enzyme Inhibitors; ErbB Receptors; Humans; Immunohistochemistry; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Signal Transduction; Tosyl Compounds; Tumor Cells, Cultured | 2001 |
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Dose-Response Relationship, Drug; Doxazosin; Humans; Male; Prazosin; Prostatic Neoplasms; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Tumor Cells, Cultured | 2002 |
Growth inhibition of prostate cancer xenografts by halofuginone.
Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Apoptosis; Collagen Type I; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Phenotype; Piperidines; Prostatic Neoplasms; Quinazolines; Quinazolinones | 2002 |
Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor.
Topics: Adenocarcinoma; Apoptosis; Blotting, Northern; Blotting, Western; Cell Count; Cell Cycle; Cell Division; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Immunohistochemistry; Male; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Phosphorylation; Prostatic Neoplasms; Quinazolines; RNA, Messenger; Signal Transduction; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2002 |
[Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Piperazines; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Quinazolines; Radioligand Assay; Receptors, Adrenergic, alpha | 1992 |
Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.
Topics: Acid Phosphatase; Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Time Factors; Trimetrexate | 1990 |